Thermo Fisher Scientific (NYSE:TMO - Get Free Report) will post its quarterly earnings results before the market opens on Wednesday, April 24th. Analysts expect Thermo Fisher Scientific to post earnings of $4.71 per share for the quarter. Thermo Fisher Scientific has set its FY 2024 guidance at 20.950-22.000 EPS and its FY24 guidance at $20.95 to $22.00 EPS.Persons interested in listening to the company's earnings conference call can do so using this link.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm's revenue was down 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.40 EPS. On average, analysts expect Thermo Fisher Scientific to post $22 EPS for the current fiscal year and $24 EPS for the next fiscal year.
Thermo Fisher Scientific Price Performance
Shares of TMO stock traded down $7.30 on Wednesday, reaching $547.25. 1,609,039 shares of the company were exchanged, compared to its average volume of 1,540,204. Thermo Fisher Scientific has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The business has a 50-day moving average price of $571.67 and a 200 day moving average price of $526.87. The company has a market cap of $208.89 billion, a price-to-earnings ratio of 35.44, a P/E/G ratio of 2.34 and a beta of 0.80.
Thermo Fisher Scientific Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date was Thursday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's payout ratio is 10.10%.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on TMO. Sanford C. Bernstein reissued a "market perform" rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Evercore ISI raised their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an "outperform" rating in a research report on Thursday, April 4th. Citigroup began coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They set a "neutral" rating and a $620.00 target price for the company. HSBC boosted their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Raymond James lifted their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an "outperform" rating in a report on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $604.69.
Read Our Latest Report on Thermo Fisher Scientific
Insider Buying and Selling at Thermo Fisher Scientific
In related news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company's stock, valued at $7,250,362. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company's stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock valued at $28,513,384 in the last ninety days. Insiders own 0.32% of the company's stock.
Institutional Investors Weigh In On Thermo Fisher Scientific
Institutional investors and hedge funds have recently modified their holdings of the company. Coppell Advisory Solutions LLC purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $33,000. Live Oak Investment Partners purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $36,000. Tyler Stone Wealth Management acquired a new position in Thermo Fisher Scientific during the second quarter valued at approximately $37,000. Grayhawk Investment Strategies Inc. boosted its position in shares of Thermo Fisher Scientific by 170.3% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 100 shares of the medical research company's stock worth $53,000 after buying an additional 63 shares during the period. Finally, Pin Oak Investment Advisors Inc. raised its stake in shares of Thermo Fisher Scientific by 27.8% during the second quarter. Pin Oak Investment Advisors Inc. now owns 115 shares of the medical research company's stock valued at $60,000 after purchasing an additional 25 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
